PRQR ProQR Therapeutics | $2.47 -3.5% | 3/14/2024 | Target Raised by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $2.00 -> $2.50 | Low | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 3/14/2024 |
SLN Silence Therapeutics | $24.01 +5.1% | 3/14/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $26.00 -> $42.00 | Low | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 3/14/2024 |
IMRX Immuneering | $2.56 +34.0% | 3/15/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $21.00 -> $16.00 | N/A | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 3/15/2024 |
GWH ESS Tech | $0.66 -5.7% | 3/15/2024 | Target Lowered by | Chardan Capital | - | Neutral -> Neutral | $1.90 -> $0.80 | N/A | View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 3/15/2024 |
NRGV Energy Vault | $1.64
| 3/18/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $7.00 | Low | View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 3/18/2024 |
DYN Dyne Therapeutics | $26.28 -6.1% | 3/8/2024 | Target Raised by | Chardan Capital | - | Buy | $20.00 -> $31.00 | Low | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/8/2024 |
|
RGNX REGENXBIO | $22.33 +0.6% | 3/7/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $52.00 | Low | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 3/7/2024 |
MCRB Seres Therapeutics | $0.76 -3.8% | 3/6/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $10.00 -> $8.00 | Low | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 3/6/2024 |
MGX Metagenomi | $11.07 +9.2% | 3/5/2024 | Initiated by | Chardan Capital | - | Buy | $21.00 | Low | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 3/5/2024 |
MARA Marathon Digital | $19.41 +0.5% | 3/4/2024 | Target Raised by | Chardan Capital | - | Neutral -> Neutral | $26.00 -> $30.00 | Low | View details for Chardan Capital rating of Marathon Digital (NASDAQ:MARA) on 3/4/2024 |
CLSK CleanSpark | $17.46 +0.2% | 3/4/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $13.00 -> $26.00 | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 3/4/2024 |
ABUS Arbutus Biopharma | $2.54 -3.1% | 3/1/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $4.00 | Low | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 3/1/2024 |
RNA Avidity Biosciences | $23.93 -2.0% | 2/29/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $23.00 | Low | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 2/29/2024 |
SLDP Solid Power | $1.35 -2.2% | 2/28/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $5.00 | Low | View details for Chardan Capital rating of Solid Power (NASDAQ:SLDP) on 2/28/2024 |
CRSP CRISPR Therapeutics | $71.47 -2.0% | 2/22/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $110.00 -> $112.00 | Low | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/22/2024 |
IOVA Iovance Biotherapeutics | $14.03 +0.9% | 2/20/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $29.00 -> $34.00 | Low | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 2/20/2024 |
ALNY Alnylam Pharmaceuticals | $147.41 -1.2% | 2/16/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $250.00 -> $225.00 | Low | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/16/2024 |
OTLK Outlook Therapeutics | $7.79 -5.6% | 2/15/2024 | Upgraded by | Chardan Capital | Analyst D. Gataulin | Neutral -> Buy | $60.00 | Low | View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 2/15/2024 |
SYBX Synlogic | $1.90 +2.7% | 2/9/2024 | Downgraded by | Chardan Capital | Analyst K. Nakae | Buy -> Neutral | | Low | View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
OCS Oculis | $11.85 +4.2% | 12/5/2023 | Initiated by | Chardan Capital | Analyst D. Gataulin | Buy | $30.00 | Low | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 12/5/2023 |
LXEO Lexeo Therapeutics | $15.71 +0.9% | 11/28/2023 | Initiated by | Chardan Capital | Analyst G. Livshits | Buy | $23.00 | Low | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
LICY Li-Cycle | $1.08 +42.1% | 11/16/2023 | Downgraded by | Chardan Capital | - | Buy -> Neutral | | Low | View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 11/16/2023 |
PRQR ProQR Therapeutics | $2.47 -3.5% | 11/8/2023 | Upgraded by | Chardan Capital | Analyst K. Nakae | Neutral -> Buy | $2.00 | Low | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 11/8/2023 |
WBX Wallbox | $1.45 -2.0% | 10/19/2023 | Downgraded by | Chardan Capital | - | Buy -> Neutral | $2.25 | Low | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 10/19/2023 |
VYGR Voyager Therapeutics | $9.09 -2.0% | 9/18/2023 | Reiterated by | Chardan Capital | Analyst G. Livshits | Neutral | | Low | View details for Chardan Capital rating of Voyager Therapeutics (NASDAQ:VYGR) on 9/18/2023 |
OTLK Outlook Therapeutics | $7.79 -5.6% | 8/31/2023 | Downgraded by | Chardan Capital | Analyst D. Gataulin | Buy -> Neutral | | Low | View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/31/2023 |
ZURA Zura Bio | $3.13 -1.9% | 8/17/2023 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy | | Low | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 8/17/2023 |
QURE uniQure | $4.97 -3.9% | 8/17/2023 | Reiterated by | Chardan Capital | Analyst Y. Livshits | Buy | | Low | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 8/17/2023 |
PPBT Purple Biotech | $0.69 -4.2% | 8/17/2023 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy | | Low | View details for Chardan Capital rating of Purple Biotech (NASDAQ:PPBT) on 8/17/2023 |
PLBY PLBY Group | $0.88 +8.7% | 8/17/2023 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $5.00 -> $4.00 | Low | View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 8/17/2023 |
SLN Silence Therapeutics | $24.01 +5.1% | 8/17/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $26.00 | Low | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 8/17/2023 |
IOVA Iovance Biotherapeutics | $14.03 +0.9% | 8/16/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $29.00 | Low | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 8/16/2023 |
LICY Li-Cycle | $1.08 +42.1% | 8/16/2023 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $8.00 -> $7.00 | Low | View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 8/16/2023 |
VLN Valens Semiconductor | $2.00 +2.0% | 8/15/2023 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $9.00 -> $5.00 | Low | View details for Chardan Capital rating of Valens Semiconductor (NYSE:VLN) on 8/15/2023 |
SNTI Senti Biosciences | $0.40 +8.1% | 8/15/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $6.00 | Low | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 8/15/2023 |
OTLK Outlook Therapeutics | $7.79 -5.6% | 8/15/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $200.00 | Low | View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/15/2023 |
TSHA Taysha Gene Therapies | $2.13 -7.4% | 8/15/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $5.00 | Low | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 8/15/2023 |
TNYA Tenaya Therapeutics | $4.82 -3.0% | 8/14/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $23.00 | Low | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/14/2023 |
GANX Gain Therapeutics | $4.36 +1.6% | 8/14/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $6.00 | Low | View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 8/14/2023 |
SYBX Synlogic | $1.90 +2.7% | 8/11/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $90.00 | Low | View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 8/11/2023 |
The only AI company you should be looking at (Ad) This is the ONLY AI company you should be watching right now.
No. It's not Nvidia, Intel, or Microsoft...
It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human.
This new drug discovery technique will change the market.
And that's why they received a $50 million investment from an AI powerhouse. Get the stock ticker here >>> |
CLSK CleanSpark | $17.46 +0.2% | 8/11/2023 | Target Raised by | Chardan Capital | - | Buy -> Buy | $10.00 -> $11.00 | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 8/11/2023 |
MGTX MeiraGTx | $6.20 -2.4% | 8/11/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $41.00 | Low | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 8/11/2023 |
FDMT 4D Molecular Therapeutics | $31.03 -1.5% | 8/11/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $31.00 | Low | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 8/11/2023 |
RCKT Rocket Pharmaceuticals | $26.52 -1.1% | 8/11/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $61.00 | Low | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 8/11/2023 |
FEMY Femasys | $1.94 +3.2% | 8/11/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $10.00 | Low | View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 8/11/2023 |
ADVM Adverum Biotechnologies | $1.77 +4.1% | 8/11/2023 | Upgraded by | Chardan Capital | Analyst D. Gataulin | Neutral -> Buy | $2.00 -> $4.00 | Low | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 8/11/2023 |
OBIO Orchestra BioMed | $5.36 +3.9% | 8/9/2023 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $20.00 | Low | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 8/9/2023 |
COYA Coya Therapeutics | $9.86 -2.7% | 8/9/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $11.00 | Low | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 8/9/2023 |
NRGV Energy Vault | $1.64
| 8/9/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $7.00 | Low | View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 8/9/2023 |
IOVA Iovance Biotherapeutics | $14.03 +0.9% | 8/9/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $29.00 | Low | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 8/9/2023 |
PET Wag! Group | $2.05 +0.5% | 8/10/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $8.00 | N/A | View details for Chardan Capital rating of Wag! Group (NASDAQ:PET) on 8/10/2023 |
SLDP Solid Power | $1.35 -2.2% | 8/10/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $5.00 | N/A | View details for Chardan Capital rating of Solid Power (NASDAQ:SLDP) on 8/10/2023 |
IPSC Century Therapeutics | $4.75 -5.0% | 8/9/2023 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $19.00 -> $17.00 | Low | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 8/9/2023 |
RNA Avidity Biosciences | $23.93 -2.0% | 8/9/2023 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $27.00 -> $23.00 | Low | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 8/9/2023 |
ARWR Arrowhead Pharmaceuticals | $28.14 -0.5% | 8/8/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $60.00 | Low | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 8/8/2023 |
ALNY Alnylam Pharmaceuticals | $147.41 -1.2% | 8/8/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $250.00 | Low | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 8/8/2023 |
CRSP CRISPR Therapeutics | $71.47 -2.0% | 8/7/2023 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $123.00 -> $110.00 | Low | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/7/2023 |
KRYS Krystal Biotech | $168.53 -2.6% | 8/7/2023 | Target Raised by | Chardan Capital | - | Buy -> Buy | $148.00 -> $153.00 | Low | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 8/7/2023 |
PASG Passage Bio | $1.46 -2.7% | 8/7/2023 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $11.00 -> $9.00 | Low | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 8/7/2023 |
MARA Marathon Digital | $19.41 +0.5% | 8/7/2023 | Downgraded by | Chardan Capital | - | Buy -> Neutral | $15.00 | Low | View details for Chardan Capital rating of Marathon Digital (NASDAQ:MARA) on 8/7/2023 |
NTLA Intellia Therapeutics | $27.37 -3.3% | 8/7/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $107.00 | Low | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 8/7/2023 |
ACHL Achilles Therapeutics | $1.10
| 8/7/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $11.00 | Low | View details for Chardan Capital rating of Achilles Therapeutics (NASDAQ:ACHL) on 8/7/2023 |
IMRX Immuneering | $2.56 +34.0% | 8/7/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $22.00 | Low | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 8/7/2023 |
ABUS Arbutus Biopharma | $2.54 -3.1% | 8/4/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $6.00 | Low | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 8/4/2023 |
DYN Dyne Therapeutics | $26.28 -6.1% | 8/4/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $20.00 | Low | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 8/4/2023 |
OMGA Omega Therapeutics | $3.52 -2.8% | 8/4/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $12.00 | Low | View details for Chardan Capital rating of Omega Therapeutics (NASDAQ:OMGA) on 8/4/2023 |
PRQR ProQR Therapeutics | $2.47 -3.5% | 8/4/2023 | Reiterated by | Chardan Capital | - | Neutral -> Neutral | $2.00 | Low | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 8/4/2023 |
MESO Mesoblast | $2.31 -4.9% | 8/4/2023 | Target Lowered by | Chardan Capital | - | Sell -> Sell | $4.00 -> $3.00 | Low | View details for Chardan Capital rating of Mesoblast (NASDAQ:MESO) on 8/4/2023 |
RGNX REGENXBIO | $22.33 +0.6% | 8/3/2023 | Reiterated by | Chardan Capital | - | Buy | $55.00 | Low | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 8/3/2023 |
EYPT EyePoint Pharmaceuticals | $21.30 -0.8% | 8/3/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $22.00 | Low | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 8/3/2023 |
EDIT Editas Medicine | $7.72 -5.0% | 8/2/2023 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $22.00 -> $19.00 | Low | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 8/2/2023 |
NRGV Energy Vault | $1.64
| 8/2/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $7.00 | Low | View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 8/2/2023 |
LICY Li-Cycle | $1.08 +42.1% | 8/1/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $8.00 | Low | View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 8/1/2023 |
BMTX BM Technologies | $1.69 +2.4% | 7/26/2023 | Target Lowered by | Chardan Capital | - | Buy | $13.00 -> $8.00 | Low | View details for Chardan Capital rating of BM Technologies (NYSE:BMTX) on 7/26/2023 |
KOD Kodiak Sciences | $5.67 -3.2% | 7/25/2023 | Downgraded by | Chardan Capital | Analyst D. Gataulin | Buy -> Neutral | | Low | View details for Chardan Capital rating of Kodiak Sciences (NASDAQ:KOD) on 7/25/2023 |
CLSK CleanSpark | $17.46 +0.2% | 7/24/2023 | Target Raised by | Chardan Capital | - | Buy | $6.00 -> $10.00 | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 7/24/2023 |
FBRX Forte Biosciences | $0.64 +3.2% | 7/16/2023 | Reiterated by | Chardan Capital | Analyst K. Nakae | Neutral | | Low | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 7/16/2023 |
DFLI Dragonfly Energy | $0.51 -3.8% | 7/13/2023 | Reiterated by | Chardan Capital | - | Buy -> Buy | $10.00 | Low | View details for Chardan Capital rating of Dragonfly Energy (NASDAQ:DFLI) on 7/13/2023 |
OUST Ouster | $4.89 +1.2% | 7/13/2023 | Upgraded by | Chardan Capital | - | Neutral -> Buy | $10.00 | Low | View details for Chardan Capital rating of Ouster (NYSE:OUST) on 7/13/2023 |
WBX Wallbox | $1.45 -2.0% | 6/30/2023 | Target Lowered by | Chardan Capital | - | Buy | $12.00 -> $11.00 | Low | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 6/30/2023 |
ZURA Zura Bio | $3.13 -1.9% | 7/10/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | | Low | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 7/10/2023 |
XLO Xilio Therapeutics | $0.68 -1.5% | 7/10/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | | Low | View details for Chardan Capital rating of Xilio Therapeutics (NASDAQ:XLO) on 7/10/2023 |
QURE uniQure | $4.97 -3.9% | 7/10/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | | Low | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 7/10/2023 |
PPBT Purple Biotech | $0.69 -4.2% | 7/10/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | | Low | View details for Chardan Capital rating of Purple Biotech (NASDAQ:PPBT) on 7/10/2023 |
IMVT Immunovant | $30.27 -0.9% | 7/10/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | | Low | View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 7/10/2023 |
IMNM Immunome | $22.10 -1.7% | 7/10/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | | Low | View details for Chardan Capital rating of Immunome (NASDAQ:IMNM) on 7/10/2023 |
FIXX Homology Medicines | $0.90 -2.2% | 7/10/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | | Low | View details for Chardan Capital rating of Homology Medicines (NASDAQ:FIXX) on 7/10/2023 |
FDMT 4D Molecular Therapeutics | $31.03 -1.5% | 7/11/2023 | Target Raised by | Chardan Capital | - | | $30.00 -> $31.00 | Low | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 7/11/2023 |
FDMT 4D Molecular Therapeutics | $31.03 -1.5% | 7/5/2023 | Initiated by | Chardan Capital | - | Buy | $30.00 | Low | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 7/5/2023 |
ZURA Zura Bio | $3.13 -1.9% | 6/14/2023 | Initiated by | Chardan Capital | Analyst M. Barcus | Buy | $14.00 | Low | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 6/14/2023 |
AI Cracks Open Largest Untapped Energy Reserve on Earth (Ad) This orb represents the largest untapped energy source in the world…
And although this energy resource is unknown by 99% of the public…
It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit |
NTLA Intellia Therapeutics | $27.37 -3.3% | 6/13/2023 | Target Lowered by | Chardan Capital | - | | $111.00 -> $107.00 | Low | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 6/13/2023 |
COYA Coya Therapeutics | $9.86 -2.7% | 6/7/2023 | Target Raised by | Chardan Capital | Analyst K. Nakae | | $9.00 -> $11.00 | Low | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 6/7/2023 |
SYBX Synlogic | $1.90 +2.7% | 6/6/2023 | Target Raised by | Chardan Capital | - | | $82.50 -> $90.00 | Low | View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 6/6/2023 |
PRST Presto Automation | $0.27 -3.6% | 6/1/2023 | Upgraded by | Chardan Capital | - | Neutral -> Buy | $4.25 -> $5.00 | N/A | View details for Chardan Capital rating of Presto Automation (NASDAQ:PRST) on 6/1/2023 |
MESO Mesoblast | $2.31 -4.9% | 5/30/2023 | Target Lowered by | Chardan Capital | - | | $5.00 -> $4.00 | Low | View details for Chardan Capital rating of Mesoblast (NASDAQ:MESO) on 5/30/2023 |
IMVT Immunovant | $30.27 -0.9% | 5/22/2023 | Target Raised by | Chardan Capital | - | | $21.00 -> $32.00 | Low | View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 5/22/2023 |
KRYS Krystal Biotech | $168.53 -2.6% | 5/22/2023 | Target Raised by | Chardan Capital | - | | $133.00 -> $148.00 | Low | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 5/22/2023 |
EYPT EyePoint Pharmaceuticals | $21.30 -0.8% | 5/18/2023 | Target Raised by | Chardan Capital | - | | $21.00 -> $22.00 | Low | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 5/18/2023 |
FBRX Forte Biosciences | $0.64 +3.2% | 5/15/2023 | Reiterated by | Chardan Capital | Analyst K. Nakae | Neutral | | Low | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 5/15/2023 |
KITT Nauticus Robotics | $0.24
| 5/12/2023 | Downgraded by | Chardan Capital | - | Buy -> Neutral | $2.50 | Low | View details for Chardan Capital rating of Nauticus Robotics (NASDAQ:KITT) on 5/12/2023 |
TNYA Tenaya Therapeutics | $4.82 -3.0% | 5/11/2023 | Target Lowered by | Chardan Capital | - | | $24.00 -> $23.00 | Low | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 5/11/2023 |
VLN Valens Semiconductor | $2.00 +2.0% | 5/11/2023 | Target Lowered by | Chardan Capital | - | Buy | $13.00 -> $12.00 | Low | View details for Chardan Capital rating of Valens Semiconductor (NYSE:VLN) on 5/11/2023 |
QURE uniQure | $4.97 -3.9% | 5/10/2023 | Target Lowered by | Chardan Capital | - | | $60.00 -> $56.00 | Low | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 5/10/2023 |
OCGN Ocugen | $1.03 -4.6% | 5/7/2023 | Target Raised by | Chardan Capital | Analyst D. Gataulin | | $3.50 -> $4.00 | Low | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 5/7/2023 |
RCKT Rocket Pharmaceuticals | $26.52 -1.1% | 5/5/2023 | Target Lowered by | Chardan Capital | - | | $63.00 -> $61.00 | Low | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/5/2023 |
RGNX REGENXBIO | $22.33 +0.6% | 5/4/2023 | Target Lowered by | Chardan Capital | - | | $61.00 -> $55.00 | Low | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 5/4/2023 |
MCRB Seres Therapeutics | $0.76 -3.8% | 4/28/2023 | Target Lowered by | Chardan Capital | - | | $12.00 -> $10.00 | Low | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 4/28/2023 |
WBX Wallbox | $1.45 -2.0% | 4/18/2023 | Reiterated by | Chardan Capital | - | Buy | $12.00 | Low | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 4/18/2023 |
IMRX Immuneering | $2.56 +34.0% | 4/18/2023 | Target Raised by | Chardan Capital | - | Buy | $18.00 -> $22.00 | Low | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 4/18/2023 |
OCGN Ocugen | $1.03 -4.6% | 4/14/2023 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy | $3.50 | Low | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 4/14/2023 |
CLSK CleanSpark | $17.46 +0.2% | 4/17/2023 | Reiterated by | Chardan Capital | - | Buy | $5.00 | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 4/17/2023 |
MARA Marathon Digital | $19.41 +0.5% | 4/3/2023 | Reiterated by | Chardan Capital | - | Buy | $15.00 | Low | View details for Chardan Capital rating of Marathon Digital (NASDAQ:MARA) on 4/3/2023 |
COYA Coya Therapeutics | $9.86 -2.7% | 3/30/2023 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy | $9.00 | Low | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/30/2023 |
RNA Avidity Biosciences | $23.93 -2.0% | 3/31/2023 | Reiterated by | Chardan Capital | - | Buy | $27.00 | N/A | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 3/31/2023 |
FEMY Femasys | $1.94 +3.2% | 3/30/2023 | Target Lowered by | Chardan Capital | - | Buy | $12.00 -> $10.00 | Low | View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 3/30/2023 |
TSHA Taysha Gene Therapies | $2.13 -7.4% | 3/29/2023 | Target Lowered by | Chardan Capital | - | Buy | $6.00 -> $5.00 | Low | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 3/29/2023 |
SYBX Synlogic | $1.90 +2.7% | 3/29/2023 | Target Lowered by | Chardan Capital | - | Buy | $105.00 -> $82.50 | Low | View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 3/29/2023 |
PRST Presto Automation | $0.27 -3.6% | 3/28/2023 | Reiterated by | Chardan Capital | - | Neutral | $4.25 | N/A | View details for Chardan Capital rating of Presto Automation (NASDAQ:PRST) on 3/28/2023 |
MARA Marathon Digital | $19.41 +0.5% | 3/28/2023 | Target Lowered by | Chardan Capital | - | Buy | $17.00 -> $15.00 | Low | View details for Chardan Capital rating of Marathon Digital (NASDAQ:MARA) on 3/28/2023 |
BMTX BM Technologies | $1.69 +2.4% | 3/29/2023 | Reiterated by | Chardan Capital | - | Buy | $13.00 | Low | View details for Chardan Capital rating of BM Technologies (NYSE:BMTX) on 3/29/2023 |
GANX Gain Therapeutics | $4.36 +1.6% | 3/27/2023 | Target Raised by | Chardan Capital | - | | $4.00 -> $5.75 | Low | View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 3/27/2023 |
OUST Ouster | $4.89 +1.2% | 3/24/2023 | Downgraded by | Chardan Capital | - | Buy -> Neutral | $10.00 | Low | View details for Chardan Capital rating of Ouster (NYSE:OUST) on 3/24/2023 |
SNTI Senti Biosciences | $0.40 +8.1% | 3/23/2023 | Target Lowered by | Chardan Capital | - | Buy | $8.00 -> $7.00 | Low | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 3/23/2023 |
IMTX Immatics | $11.83 -1.5% | 3/23/2023 | Target Lowered by | Chardan Capital | - | Buy | $28.00 -> $25.00 | Low | View details for Chardan Capital rating of Immatics (NASDAQ:IMTX) on 3/23/2023 |
COYA Coya Therapeutics | $9.86 -2.7% | 3/22/2023 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy | $9.00 | Low | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/22/2023 |
ANIX Anixa Biosciences | $3.51 -4.9% | 3/22/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | $8.00 -> $9.00 | Low | View details for Chardan Capital rating of Anixa Biosciences (NASDAQ:ANIX) on 3/22/2023 |
CABA Cabaletta Bio | $17.98 -4.1% | 3/22/2023 | Reiterated by | Chardan Capital | - | Buy | $12.00 | Low | View details for Chardan Capital rating of Cabaletta Bio (NASDAQ:CABA) on 3/22/2023 |
IPSC Century Therapeutics | $4.75 -5.0% | 3/22/2023 | Reiterated by | Chardan Capital | Analyst G. Livshits | Buy | $19.00 | Low | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 3/22/2023 |
IMNM Immunome | $22.10 -1.7% | 3/16/2023 | Target Lowered by | Chardan Capital | - | Buy | $9.00 -> $8.00 | Low | View details for Chardan Capital rating of Immunome (NASDAQ:IMNM) on 3/16/2023 |
CRGO Freightos | $2.50 -0.8% | 3/16/2023 | Target Lowered by | Chardan Capital | - | Buy | $13.00 -> $11.00 | Low | View details for Chardan Capital rating of Freightos (NASDAQ:CRGO) on 3/16/2023 |
MGTX MeiraGTx | $6.20 -2.4% | 3/16/2023 | Target Lowered by | Chardan Capital | - | Buy | $47.00 -> $41.00 | Low | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 3/16/2023 |
SLN Silence Therapeutics | $24.01 +5.1% | 3/16/2023 | Target Lowered by | Chardan Capital | - | Buy | $29.00 -> $26.00 | Low | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 3/16/2023 |
NRGV Energy Vault | $1.64
| 3/9/2023 | Target Lowered by | Chardan Capital | - | Buy | $13.00 -> $7.00 | Low | View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 3/9/2023 |
TNYA Tenaya Therapeutics | $4.82 -3.0% | 3/9/2023 | Target Lowered by | Chardan Capital | - | Buy | $28.00 -> $24.00 | Low | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/9/2023 |
MCRB Seres Therapeutics | $0.76 -3.8% | 3/8/2023 | Reiterated by | Chardan Capital | - | Buy | $12.00 | Low | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 3/8/2023 |
ACHL Achilles Therapeutics | $1.10
| 3/8/2023 | Target Lowered by | Chardan Capital | - | | $17.00 -> $12.00 | Low | View details for Chardan Capital rating of Achilles Therapeutics (NASDAQ:ACHL) on 3/8/2023 |
IMRX Immuneering | $2.56 +34.0% | 3/7/2023 | Reiterated by | Chardan Capital | - | Buy | $18.00 | N/A | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 3/7/2023 |
EYPT EyePoint Pharmaceuticals | $21.30 -0.8% | 3/3/2023 | Reiterated by | Chardan Capital | - | Buy | $21.00 | Low | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 3/3/2023 |
GWH ESS Tech | $0.66 -5.7% | 3/3/2023 | Target Lowered by | Chardan Capital | - | Neutral | $4.50 -> $1.80 | Low | View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 3/3/2023 |
VLN Valens Semiconductor | $2.00 +2.0% | 3/3/2023 | Reiterated by | Chardan Capital | - | Buy | $13.00 | Low | View details for Chardan Capital rating of Valens Semiconductor (NYSE:VLN) on 3/3/2023 |
Claim Your Complimentary Bitcoin Reward (Ad) Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you?
In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants.
Absolutely no strings attached. Secure Your Spot Now |
ABUS Arbutus Biopharma | $2.54 -3.1% | 3/3/2023 | Reiterated by | Chardan Capital | - | Buy | $6.00 | Low | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 3/3/2023 |
DYN Dyne Therapeutics | $26.28 -6.1% | 3/3/2023 | Target Raised by | Chardan Capital | - | Buy | $17.00 -> $20.00 | Low | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/3/2023 |
RGNX REGENXBIO | $22.33 +0.6% | 3/2/2023 | Reiterated by | Chardan Capital | - | Buy | $61.00 | Low | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 3/2/2023 |
IOVA Iovance Biotherapeutics | $14.03 +0.9% | 3/1/2023 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy | $29.00 | Low | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 3/1/2023 |
MESO Mesoblast | $2.31 -4.9% | 3/1/2023 | Reiterated by | Chardan Capital | - | Sell | $5.00 | Low | View details for Chardan Capital rating of Mesoblast (NASDAQ:MESO) on 3/1/2023 |
RNA Avidity Biosciences | $23.93 -2.0% | 3/1/2023 | Reiterated by | Chardan Capital | - | Buy | $27.00 | Low | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 3/1/2023 |
OCGN Ocugen | $1.03 -4.6% | 3/1/2023 | Upgraded by | Chardan Capital | Analyst D. Gataulin | Neutral -> Buy | $3.50 | Low | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/1/2023 |
RCKT Rocket Pharmaceuticals | $26.52 -1.1% | 3/1/2023 | Target Lowered by | Chardan Capital | - | Buy | $65.00 -> $63.00 | Low | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 3/1/2023 |
KRYS Krystal Biotech | $168.53 -2.6% | 2/28/2023 | Reiterated by | Chardan Capital | - | Buy | $133.00 | Low | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 2/28/2023 |
QURE uniQure | $4.97 -3.9% | 2/28/2023 | Reiterated by | Chardan Capital | - | Buy | $60.00 | Low | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 2/28/2023 |
LICY Li-Cycle | $1.08 +42.1% | 2/28/2023 | Reiterated by | Chardan Capital | - | Buy | $10.00 | Low | View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 2/28/2023 |
CRGO Freightos | $2.50 -0.8% | 2/28/2023 | Reiterated by | Chardan Capital | - | Buy | | Low | View details for Chardan Capital rating of Freightos (NASDAQ:CRGO) on 2/28/2023 |
NTLA Intellia Therapeutics | $27.37 -3.3% | 2/24/2023 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy | $129.00 -> $111.00 | Low | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/24/2023 |
WBX Wallbox | $1.45 -2.0% | 2/24/2023 | Target Lowered by | Chardan Capital | - | Buy | $13.00 -> $12.00 | Low | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 2/24/2023 |
ALNY Alnylam Pharmaceuticals | $147.41 -1.2% | 2/24/2023 | Reiterated by | Chardan Capital | - | Buy | $250.00 | Low | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/24/2023 |
EDIT Editas Medicine | $7.72 -5.0% | 2/23/2023 | Target Lowered by | Chardan Capital | - | Buy | $35.00 -> $22.00 | Low | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 2/23/2023 |
PET Wag! Group | $2.05 +0.5% | 2/22/2023 | Target Raised by | Chardan Capital | - | Buy | $5.00 -> $8.00 | Low | View details for Chardan Capital rating of Wag! Group (NASDAQ:PET) on 2/22/2023 |
CRSP CRISPR Therapeutics | $71.47 -2.0% | 2/22/2023 | Target Lowered by | Chardan Capital | - | Buy | $153.00 -> $123.00 | Low | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/22/2023 |
PRST Presto Automation | $0.27 -3.6% | 2/16/2023 | Reiterated by | Chardan Capital | - | Neutral | $4.25 | N/A | View details for Chardan Capital rating of Presto Automation (NASDAQ:PRST) on 2/16/2023 |
PLBY PLBY Group | $0.88 +8.7% | 2/13/2023 | Reiterated by | Chardan Capital | - | Buy | $5.00 | Low | View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 2/13/2023 |
DFLI Dragonfly Energy | $0.51 -3.8% | 2/10/2023 | Target Lowered by | Chardan Capital | - | Buy | $15.00 -> $10.00 | Low | View details for Chardan Capital rating of Dragonfly Energy (NASDAQ:DFLI) on 2/10/2023 |
ARWR Arrowhead Pharmaceuticals | $28.14 -0.5% | 2/10/2023 | Reiterated by | Chardan Capital | - | Buy | $60.00 | Low | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/10/2023 |
PPBT Purple Biotech | $0.69 -4.2% | 2/9/2023 | Reiterated by | Chardan Capital | Analyst M. Barcus | Buy | $11.00 | Low | View details for Chardan Capital rating of Purple Biotech (NASDAQ:PPBT) on 2/9/2023 |
BMTX BM Technologies | $1.69 +2.4% | 2/7/2023 | Target Lowered by | Chardan Capital | - | Buy | $21.00 -> $13.00 | Low | View details for Chardan Capital rating of BM Technologies (NYSE:BMTX) on 2/7/2023 |
OBIO Orchestra BioMed | $5.36 +3.9% | 2/7/2023 | Initiated by | Chardan Capital | Analyst K. Nakae | Buy | $20.00 | Low | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 2/7/2023 |
IMVT Immunovant | $30.27 -0.9% | 2/5/2023 | Target Raised by | Chardan Capital | - | Buy | $19.00 -> $21.00 | Low | View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 2/5/2023 |
TSHA Taysha Gene Therapies | $2.13 -7.4% | 2/1/2023 | Target Lowered by | Chardan Capital | - | Buy | $16.00 -> $6.00 | Low | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 2/1/2023 |
LICY Li-Cycle | $1.08 +42.1% | 1/31/2023 | Target Lowered by | Chardan Capital | - | Buy | $13.00 -> $10.00 | Low | View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 1/31/2023 |
SNTI Senti Biosciences | $0.40 +8.1% | 1/27/2023 | Target Lowered by | Chardan Capital | - | Buy | $12.00 -> $8.00 | Low | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 1/27/2023 |
COYA Coya Therapeutics | $9.86 -2.7% | 1/26/2023 | Initiated by | Chardan Capital | Analyst K. Nakae | Buy | $9.00 | N/A | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 1/26/2023 |
MRNA Moderna | $104.26 +0.4% | 1/18/2023 | Target Raised by | Chardan Capital | Analyst Y. Livshits | Neutral | $191.00 -> $208.00 | Low | View details for Chardan Capital rating of Moderna (NASDAQ:MRNA) on 1/18/2023 |
ARWR Arrowhead Pharmaceuticals | $28.14 -0.5% | 1/10/2023 | Target Lowered by | Chardan Capital | - | | $82.00 -> $60.00 | Low | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 1/10/2023 |
IPSC Century Therapeutics | $4.75 -5.0% | 12/27/2022 | Initiated by | Chardan Capital | Analyst G. Livshits | Buy | $19.00 | Low | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 12/27/2022 |
ANIX Anixa Biosciences | $3.51 -4.9% | 12/23/2022 | Initiated by | Chardan Capital | - | Buy | $8.00 | Low | View details for Chardan Capital rating of Anixa Biosciences (NASDAQ:ANIX) on 12/23/2022 |
XLO Xilio Therapeutics | $0.68 -1.5% | 12/21/2022 | Initiated by | Chardan Capital | Analyst M. Barcus | Buy | $7.00 | Low | View details for Chardan Capital rating of Xilio Therapeutics (NASDAQ:XLO) on 12/21/2022 |
CLSK CleanSpark | $17.46 +0.2% | 12/15/2022 | Target Lowered by | Chardan Capital | - | Buy | $6.00 -> $5.00 | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 12/15/2022 |
PASG Passage Bio | $1.46 -2.7% | 12/15/2022 | Target Lowered by | Chardan Capital | - | Buy | $18.00 -> $11.00 | Low | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 12/15/2022 |
MRNA Moderna | $104.26 +0.4% | 12/14/2022 | Downgraded by | Chardan Capital | Analyst Y. Livshits | Buy -> Neutral | $186.00 -> $191.00 | Low | View details for Chardan Capital rating of Moderna (NASDAQ:MRNA) on 12/14/2022 |
PRST Presto Automation | $0.27 -3.6% | 12/9/2022 | Initiated by | Chardan Capital | - | Neutral | $4.25 | N/A | View details for Chardan Capital rating of Presto Automation (NASDAQ:PRST) on 12/9/2022 |
GANX Gain Therapeutics | $4.36 +1.6% | 12/9/2022 | Initiated by | Chardan Capital | - | Buy | $4.00 | Low | View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 12/9/2022 |
ACHL Achilles Therapeutics | $1.10
| 12/6/2022 | Target Lowered by | Chardan Capital | - | Buy | $20.00 -> $17.00 | Low | View details for Chardan Capital rating of Achilles Therapeutics (NASDAQ:ACHL) on 12/6/2022 |
IOVA Iovance Biotherapeutics | $14.03 +0.9% | 11/18/2022 | Target Lowered by | Chardan Capital | - | Buy | $30.00 -> $29.00 | Low | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 11/18/2022 |
DFLI Dragonfly Energy | $0.51 -3.8% | 11/18/2022 | Initiated by | Chardan Capital | - | Buy | $15.00 | Low | View details for Chardan Capital rating of Dragonfly Energy (NASDAQ:DFLI) on 11/18/2022 |
EDIT Editas Medicine | $7.72 -5.0% | 11/17/2022 | Target Lowered by | Chardan Capital | - | Buy | $43.00 -> $35.00 | Low | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 11/17/2022 |
SLN Silence Therapeutics | $24.01 +5.1% | 11/17/2022 | Target Lowered by | Chardan Capital | - | Buy | $33.00 -> $29.00 | Low | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 11/17/2022 |
FIXX Homology Medicines | $0.90 -2.2% | 11/17/2022 | Target Lowered by | Chardan Capital | Analyst M. Barcus | Buy -> Buy | $10.00 -> $8.00 | Low | View details for Chardan Capital rating of Homology Medicines (NASDAQ:FIXX) on 11/17/2022 |
VINC Vincerx Pharma | $4.91 -12.0% | 11/16/2022 | Target Lowered by | Chardan Capital | - | Buy | $4.00 -> $3.00 | Low | View details for Chardan Capital rating of Vincerx Pharma (NASDAQ:VINC) on 11/16/2022 |
PDSB PDS Biotechnology | $4.76 -3.1% | 11/14/2022 | Target Raised by | Chardan Capital | - | Buy | $15.00 -> $16.00 | Low | View details for Chardan Capital rating of PDS Biotechnology (NASDAQ:PDSB) on 11/14/2022 |
NTLA Intellia Therapeutics | $27.37 -3.3% | 11/14/2022 | Target Raised by | Chardan Capital | Analyst Geulah Livshits | Buy | $121.00 -> $129.00 | Low | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 11/14/2022 |
CABA Cabaletta Bio | $17.98 -4.1% | 11/11/2022 | Target Lowered by | Chardan Capital | - | Buy | $13.00 -> $12.00 | Low | View details for Chardan Capital rating of Cabaletta Bio (NASDAQ:CABA) on 11/11/2022 |
Make This $3 Trade the Instant the Opening Bell Rings (Ad) Since the birth of Wall Street, one simple rule has remained the same....
Buy stocks that are cheap....When they’re on sale….
And when nobody else is looking… See Why This $3.00 Stock Could Hit $15.00 |
ADVM Adverum Biotechnologies | $1.77 +4.1% | 11/11/2022 | Target Lowered by | Chardan Capital | - | Neutral | $2.50 -> $2.00 | Low | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 11/11/2022 |
TNYA Tenaya Therapeutics | $4.82 -3.0% | 11/11/2022 | Target Lowered by | Chardan Capital | - | Buy | $30.00 -> $28.00 | Low | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/11/2022 |
SYBX Synlogic | $1.90 +2.7% | 11/11/2022 | Target Lowered by | Chardan Capital | Analyst Keay Nakae | Buy | $135.00 -> $105.00 | Low | View details for Chardan Capital rating of Synlogic (NASDAQ:SYBX) on 11/11/2022 |
FEMY Femasys | $1.94 +3.2% | 11/11/2022 | Target Lowered by | Chardan Capital | - | Buy | $15.00 -> $12.00 | Low | View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 11/11/2022 |
PHGE BiomX | $0.36
| 11/9/2022 | Target Lowered by | Chardan Capital | - | Buy | $6.00 -> $2.00 | N/A | View details for Chardan Capital rating of BiomX (NYSEMKT:PHGE) on 11/9/2022 |
TSHA Taysha Gene Therapies | $2.13 -7.4% | 11/9/2022 | Target Lowered by | Chardan Capital | - | Buy | $32.00 -> $16.00 | Low | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 11/9/2022 |
EBS Emergent BioSolutions | $2.48 +0.8% | 11/9/2022 | Target Lowered by | Chardan Capital | - | Buy | $65.00 -> $55.00 | Low | View details for Chardan Capital rating of Emergent BioSolutions (NYSE:EBS) on 11/9/2022 |
VTRS Viatris | $11.76 -1.5% | 11/7/2022 | Downgraded by | Chardan Capital | - | Buy -> Neutral | | N/A | View details for Chardan Capital rating of Viatris (NASDAQ:VTRS) on 11/7/2022 |
KRYS Krystal Biotech | $168.53 -2.6% | 11/7/2022 | Target Raised by | Chardan Capital | - | Buy | $130.00 -> $133.00 | Low | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 11/7/2022 |
IMVT Immunovant | $30.27 -0.9% | 11/7/2022 | Target Raised by | Chardan Capital | - | Buy | $12.00 -> $19.00 | Low | View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 11/7/2022 |
MRNA Moderna | $104.26 +0.4% | 11/7/2022 | Target Lowered by | Chardan Capital | - | Buy | $188.00 -> $186.00 | Low | View details for Chardan Capital rating of Moderna (NASDAQ:MRNA) on 11/7/2022 |
GWH ESS Tech | $0.66 -5.7% | 11/4/2022 | Target Lowered by | Chardan Capital | - | Neutral | $5.00 -> $4.50 | Low | View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 11/4/2022 |
RGNX REGENXBIO | $22.33 +0.6% | 11/4/2022 | Target Lowered by | Chardan Capital | - | Buy | $70.00 -> $61.00 | Low | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 11/4/2022 |
NTLA Intellia Therapeutics | $27.37 -3.3% | 11/3/2022 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy | $146.00 -> $121.00 | Low | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 11/3/2022 |
EDIT Editas Medicine | $7.72 -5.0% | 11/2/2022 | Target Lowered by | Chardan Capital | - | Buy | $60.00 -> $43.00 | Low | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 11/2/2022 |
CLSK CleanSpark | $17.46 +0.2% | 10/28/2022 | Target Lowered by | Chardan Capital | - | Buy | $9.00 -> $6.00 | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 10/28/2022 |
PLBY PLBY Group | $0.88 +8.7% | 10/21/2022 | Target Lowered by | Chardan Capital | - | Buy | $9.00 -> $5.00 | Low | View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 10/21/2022 |
KITT Nauticus Robotics | $0.24
| 10/10/2022 | Initiated by | Chardan Capital | - | Buy | $11.00 | Low | View details for Chardan Capital rating of Nauticus Robotics (NASDAQ:KITT) on 10/10/2022 |
RCKT Rocket Pharmaceuticals | $26.52 -1.1% | 9/30/2022 | Target Raised by | Chardan Capital | - | Buy | $62.00 -> $65.00 | Low | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 9/30/2022 |
PET Wag! Group | $2.05 +0.5% | 9/30/2022 | Initiated by | Chardan Capital | - | Buy | $5.00 | Low | View details for Chardan Capital rating of Wag! Group (NASDAQ:PET) on 9/30/2022 |
IMVT Immunovant | $30.27 -0.9% | 9/29/2022 | Target Lowered by | Chardan Capital | Analyst M. Barcus | Buy | $14.00 -> $12.00 | Low | View details for Chardan Capital rating of Immunovant (NASDAQ:IMVT) on 9/29/2022 |
RNA Avidity Biosciences | $23.93 -2.0% | 9/27/2022 | Target Lowered by | Chardan Capital | Analyst K. Nakae | Buy | $29.00 -> $27.00 | Low | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 9/27/2022 |
OMGA Omega Therapeutics | $3.52 -2.8% | 9/23/2022 | Initiated by | Chardan Capital | - | Buy | $12.00 | Low | View details for Chardan Capital rating of Omega Therapeutics (NASDAQ:OMGA) on 9/23/2022 |
SNTI Senti Biosciences | $0.40 +8.1% | 9/22/2022 | Initiated by | Chardan Capital | - | Buy | $12.00 | Low | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 9/22/2022 |
NTLA Intellia Therapeutics | $27.37 -3.3% | 9/16/2022 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy | $146.00 | Low | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 9/16/2022 |
LICY Li-Cycle | $1.08 +42.1% | 9/15/2022 | Target Lowered by | Chardan Capital | - | Buy | $18.00 -> $13.00 | Low | View details for Chardan Capital rating of Li-Cycle (NYSE:LICY) on 9/15/2022 |
OTLK Outlook Therapeutics | $7.79 -5.6% | 9/13/2022 | Initiated by | Chardan Capital | - | Buy | | Low | View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 9/13/2022 |
PPBT Purple Biotech | $0.69 -4.2% | 9/8/2022 | Initiated by | Chardan Capital | Analyst M. Barcus | Buy | $11.00 | Low | View details for Chardan Capital rating of Purple Biotech (NASDAQ:PPBT) on 9/8/2022 |
FBRX Forte Biosciences | $0.64 +3.2% | 8/17/2022 | Downgraded by | Chardan Capital | Analyst K. Nakae | Buy -> Neutral | | Low | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 8/17/2022 |
FIXX Homology Medicines | $0.90 -2.2% | 8/16/2022 | Target Lowered by | Chardan Capital | Analyst M. Barcus | Buy -> Buy | $14.00 -> $10.00 | Low | View details for Chardan Capital rating of Homology Medicines (NASDAQ:FIXX) on 8/16/2022 |
GWH ESS Tech | $0.66 -5.7% | 8/15/2022 | Target Raised by | Chardan Capital | - | Neutral | $3.50 -> $5.00 | Low | View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 8/15/2022 |
CLSK CleanSpark | $17.46 +0.2% | 8/15/2022 | Target Raised by | Chardan Capital | - | Buy | $7.00 -> $9.00 | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 8/15/2022 |
ADVM Adverum Biotechnologies | $1.77 +4.1% | 8/12/2022 | Target Lowered by | Chardan Capital | Analyst D. Gataulin | Neutral | $3.00 -> $2.50 | Low | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 8/12/2022 |
MGTX MeiraGTx | $6.20 -2.4% | 8/12/2022 | Target Raised by | Chardan Capital | Analyst Geulah Livshits | Buy | $46.00 -> $47.00 | Low | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 8/12/2022 |
TSHA Taysha Gene Therapies | $2.13 -7.4% | 8/12/2022 | Target Lowered by | Chardan Capital | - | Buy | $34.00 -> $32.00 | Low | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 8/12/2022 |
SLDB Solid Biosciences | $13.36 +2.1% | 8/12/2022 | Target Lowered by | Chardan Capital | - | Buy | $105.00 -> $90.00 | Low | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 8/12/2022 |
CABA Cabaletta Bio | $17.98 -4.1% | 8/12/2022 | Target Lowered by | Chardan Capital | - | Buy | $17.00 -> $13.00 | Low | View details for Chardan Capital rating of Cabaletta Bio (NASDAQ:CABA) on 8/12/2022 |
PRQR ProQR Therapeutics | $2.47 -3.5% | 8/12/2022 | Downgraded by | Chardan Capital | Analyst K. Nakae | Buy -> Neutral | | Low | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 8/12/2022 |
SABS SAB Biotherapeutics | $5.40 -2.2% | 8/11/2022 | Target Lowered by | Chardan Capital | - | Buy | $7.00 -> $3.00 | Low | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 8/11/2022 |
TNYA Tenaya Therapeutics | $4.82 -3.0% | 8/11/2022 | Target Lowered by | Chardan Capital | - | Buy | $31.00 -> $30.00 | Low | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/11/2022 |
IMTX Immatics | $11.83 -1.5% | 8/10/2022 | Target Lowered by | Chardan Capital | - | Buy | $30.00 -> $28.00 | Low | View details for Chardan Capital rating of Immatics (NASDAQ:IMTX) on 8/10/2022 |
KOD Kodiak Sciences | $5.67 -3.2% | 8/10/2022 | Target Lowered by | Chardan Capital | Analyst D. Gataulin | Buy | $19.00 -> $18.00 | Low | View details for Chardan Capital rating of Kodiak Sciences (NASDAQ:KOD) on 8/10/2022 |
PLBY PLBY Group | $0.88 +8.7% | 8/10/2022 | Target Lowered by | Chardan Capital | - | Buy | $13.00 -> $9.00 | Low | View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 8/10/2022 |
QURE uniQure | $4.97 -3.9% | 8/9/2022 | Target Lowered by | Chardan Capital | Analyst M. Barcus | Buy | $65.00 -> $60.00 | Low | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 8/9/2022 |
CRSP CRISPR Therapeutics | $71.47 -2.0% | 8/9/2022 | Target Lowered by | Chardan Capital | - | Buy | $164.00 -> $154.00 | Low | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/9/2022 |
KRYS Krystal Biotech | $168.53 -2.6% | 8/9/2022 | Target Lowered by | Chardan Capital | - | Buy | $137.00 -> $130.00 | Low | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 8/9/2022 |
ARWR Arrowhead Pharmaceuticals | $28.14 -0.5% | 8/5/2022 | Target Raised by | Chardan Capital | - | | $80.00 -> $82.00 | Low | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 8/5/2022 |
IOVA Iovance Biotherapeutics | $14.03 +0.9% | 8/5/2022 | Target Lowered by | Chardan Capital | - | | $31.00 -> $30.00 | Low | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 8/5/2022 |
PASG Passage Bio | $1.46 -2.7% | 8/5/2022 | Target Lowered by | Chardan Capital | - | | $34.00 -> $18.00 | Low | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 8/5/2022 |
NTLA Intellia Therapeutics | $27.37 -3.3% | 8/5/2022 | Target Lowered by | Chardan Capital | - | Buy | $172.00 -> $146.00 | Low | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 8/5/2022 |
MCRB Seres Therapeutics | $0.76 -3.8% | 8/4/2022 | Target Lowered by | Chardan Capital | - | | $16.00 -> $12.00 | Low | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 8/4/2022 |
ALNY Alnylam Pharmaceuticals | $147.41 -1.2% | 8/4/2022 | Target Raised by | Chardan Capital | Analyst Keay Nakae | Buy | $200.00 -> $250.00 | Low | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 8/4/2022 |
PLBY PLBY Group | $0.88 +8.7% | 8/3/2022 | Target Lowered by | Chardan Capital | - | Buy | $21.00 -> $13.00 | Low | View details for Chardan Capital rating of PLBY Group (NASDAQ:PLBY) on 8/3/2022 |
DYN Dyne Therapeutics | $26.28 -6.1% | 7/20/2022 | Initiated by | Chardan Capital | - | Buy | $17.00 | Low | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 7/20/2022 |
RNA Avidity Biosciences | $23.93 -2.0% | 7/20/2022 | Initiated by | Chardan Capital | Analyst K. Nakae | Buy | $29.00 | Low | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 7/20/2022 |
IMRX Immuneering | $2.56 +34.0% | 7/8/2022 | Initiated by | Chardan Capital | - | Buy | $18.00 | N/A | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 7/8/2022 |
EYPT EyePoint Pharmaceuticals | $21.30 -0.8% | 7/7/2022 | Initiated by | Chardan Capital | Analyst D. Gataulin | Buy | $21.00 | N/A | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 7/7/2022 |
SLDP Solid Power | $1.35 -2.2% | 6/29/2022 | Initiated by | Chardan Capital | - | Buy | $8.00 | Low | View details for Chardan Capital rating of Solid Power (NASDAQ:SLDP) on 6/29/2022 |
NRGV Energy Vault | $1.64
| 6/29/2022 | Initiated by | Chardan Capital | - | Buy | $13.00 | Low | View details for Chardan Capital rating of Energy Vault (NYSE:NRGV) on 6/29/2022 |
GWH ESS Tech | $0.66 -5.7% | 6/29/2022 | Initiated by | Chardan Capital | - | Neutral | $3.50 | Low | View details for Chardan Capital rating of ESS Tech (NYSE:GWH) on 6/29/2022 |